Limits...
Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.

Vedel-Krogh S, Nielsen SF, Nordestgaard BG - PLoS ONE (2015)

Bottom Line: Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years.Results were robust in all sensitivity analyses.Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Herlev and Gentofte Hospitals, Copenhagen University Hospital, Herlev, Denmark.

ABSTRACT

Introduction: We hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality.

Methods: We studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study.

Results: The cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786 + 3,572) and idiopathic lung fibrosis (n = 261 + 522) was higher for statin users versus never users (log-rank: P = 7 · 10(-9) and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses.

Conclusion: Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

No MeSH data available.


Related in: MedlinePlus

Inclusion of interstitial lung disease patients during 1995 through 2009.Patients were divided into regular statin users and never users. A, Entire Danish population. B. Nested 1:2 matched study.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608706&req=5

pone.0140571.g001: Inclusion of interstitial lung disease patients during 1995 through 2009.Patients were divided into regular statin users and never users. A, Entire Danish population. B. Nested 1:2 matched study.

Mentions: We included patients from the entire Danish population aged 40 years or older who had received a diagnosis of interstitial lung disease between 1995 and 2009, and followed them until December 31, 2011 (median, 2.5 years; range, 0 to 16.5); we identified a total of 22,941 patients with interstitial lung disease aged 40 or older, of whom 5,915 had idiopathic lung fibrosis. By including only patients who received a diagnosis of interstitial lung disease through 2009, we allowed at least 2 years of follow-up time for all patients. Due to an increase in the use of statins (Fig 1) and possible changes in diagnosis and treatment of interstitial lung disease over time, we conducted a nested 1:2 matched study. In the matched study, we grouped 1,786 as regular statin users up until the time of the interstitial lung disease diagnosis, whereas 3,572 had never used statins (Fig 2).


Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.

Vedel-Krogh S, Nielsen SF, Nordestgaard BG - PLoS ONE (2015)

Inclusion of interstitial lung disease patients during 1995 through 2009.Patients were divided into regular statin users and never users. A, Entire Danish population. B. Nested 1:2 matched study.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608706&req=5

pone.0140571.g001: Inclusion of interstitial lung disease patients during 1995 through 2009.Patients were divided into regular statin users and never users. A, Entire Danish population. B. Nested 1:2 matched study.
Mentions: We included patients from the entire Danish population aged 40 years or older who had received a diagnosis of interstitial lung disease between 1995 and 2009, and followed them until December 31, 2011 (median, 2.5 years; range, 0 to 16.5); we identified a total of 22,941 patients with interstitial lung disease aged 40 or older, of whom 5,915 had idiopathic lung fibrosis. By including only patients who received a diagnosis of interstitial lung disease through 2009, we allowed at least 2 years of follow-up time for all patients. Due to an increase in the use of statins (Fig 1) and possible changes in diagnosis and treatment of interstitial lung disease over time, we conducted a nested 1:2 matched study. In the matched study, we grouped 1,786 as regular statin users up until the time of the interstitial lung disease diagnosis, whereas 3,572 had never used statins (Fig 2).

Bottom Line: Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years.Results were robust in all sensitivity analyses.Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Herlev and Gentofte Hospitals, Copenhagen University Hospital, Herlev, Denmark.

ABSTRACT

Introduction: We hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality.

Methods: We studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study.

Results: The cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786 + 3,572) and idiopathic lung fibrosis (n = 261 + 522) was higher for statin users versus never users (log-rank: P = 7 · 10(-9) and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses.

Conclusion: Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

No MeSH data available.


Related in: MedlinePlus